Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NDRA vs CDNA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CDNA Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

CDNA Overall Winner 6-Pillar Tally: NDRA 0 – 6 CDNA Matrix Metrics: NDRA 2 – 8 CDNA

As of Nov 16, 2026, CareDx, Inc. (CDNA) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NDRA carries a Unified Composite Score of 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin), whereas CDNA carries 24.5/100 (STRONG SELL) at $73.72 (47.1x Forward P/E, 1.6% operating margin).

  • Composite vs. Pillar Nuance: While NDRA currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. CDNA 24.5/100 STRONG SELL), CDNA captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (1.6% vs. 0.0% operating margin) and revenue trajectory (+39.3% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: NDRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7); meanwhile CDNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 49.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NDRA vs CDNA
NDRA NASDAQ
ENDRA Life Sciences Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$4.42
+0.23% 1D
Market Cap $6.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.71β · 48% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 35.0 Fund 46.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.3%), weak momentum, RSI 37
RSI-14: 36.7 · SMA20: $4.75 · SMA50: $5.32
CDNA NASDAQ Head-to-Head Winner
CareDx, Inc.
Services-Medical Laboratories
$73.72
-5.34% 1D
Market Cap $4.1B
TTM Revenue $497M
Forward P/E 47.1x
Beta / 30D Vol 1.21β · 98% Vol
Unified Composite Score
24.5 / 100 STRONG SELL
Tech 15.0 Fund 36.0 Flow 70.0 Mom 25.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 49.0 · SMA20: $77.09 · SMA50: $66.80

6-Pillar Scorecard Institutional Category Breakdown (NDRA 0 – 6 CDNA)

Columns: Metric · NDRA · CDNA
1. Valuation Multiples CDNA
Forward P/E N/M 47.1x
Trailing P/E N/M 32.9x
PEG Ratio N/M N/M
EV / Revenue N/M 7.8x
2. Growth & Scale CDNA
Revenue Growth (YoY) +0.0% +39.3%
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) N/A $497M
Market Cap $6.6M $4.1B
3. Profitability & Quality CDNA
Gross Margin N/A 71.0%
Operating Margin 0.0% 1.6%
Net Profit Margin 0.0% 25.9%
Return on Equity (ROE) -152.0% 33.0%
4. Balance Sheet & Cash Flow CDNA
Cash Generation (TTM) -$8.0M $60M
Cash Flow Margin N/A 12.0%
Net Cash / Leverage $104,744 Net Debt (0.26x D/E) $221M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CDNA
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 56.8% (18th %ile)
Put/Call OI Skew N/A 1.04x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat CDNA
OpEx & R&D Intensity N/A 69.4% of Rev ($345M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NDRA (2) vs CDNA (8)
Institutional Metric NDRA CDNA Criterion Row Edge
Market Capitalization
Scale
$6.6M $4.1B Larger Scale CDNA
Trailing P/E Ratio
Valuation
N/M 32.9x Lower Multiple CDNA
Forward P/E Ratio
Valuation
N/M 47.1x Lower Multiple CDNA
Revenue Growth (YoY)
Growth
+0.0% +39.3% Higher Growth CDNA
Operating Margin (TTM)
Profitability
0.0% 1.6% Higher Margin CDNA
Net Profit Margin
Profitability
0.0% 25.9% Higher Margin CDNA
Return on Equity (ROE)
Capital Efficiency
-152.0% 33.0% Higher ROE CDNA
52-Week Range Position
Momentum
37% ($3–$7) 77% ($15–$91) Stronger Trend CDNA
Beta / 30D Volatility
Risk Regime
0.71β · 48% Vol 1.21β · 98% Vol Lower Realized Risk NDRA
Unified Institutional Score
Composite Signal
44.7 / 100 (HOLD) 24.5 / 100 (STRONG SELL) Higher Composite NDRA
Trailing 12M Revenue (USD)
Operating Scale
N/A $497M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 71.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 7.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$8.0M ($104,744 Net Debt (0.26x D/E)) $60M ($221M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CDNA +21.94 pp
NDRA: -6.75% · CDNA: +15.19%
3M Horizon CDNA +61.64 pp
NDRA: -2.0% · CDNA: +59.64%
6M Horizon CDNA +276.34 pp
NDRA: -18.3% · CDNA: +258.04%
1Y Horizon CDNA +397.24 pp
NDRA: -32.72% · CDNA: +364.52%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NDRA Revenue CDNA Revenue NDRA Op. Margin CDNA Op. Margin Margin Leader
FY2018 $0M $80M -146080.5% -20.3% CDNA
FY2019 N/A $130M N/A -19.3% CDNA
FY2020 N/A $190M N/A -11.7% CDNA
FY2021 N/A $300M N/A -10.0% CDNA
FY2022 N/A $320M N/A -24.0% CDNA
FY2023 N/A $280M N/A -72.5% CDNA
FY2024 N/A $330M N/A 12.2% CDNA
FY2025 N/A $380M N/A -8.1% CDNA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NDRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NDRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CDNA CONSOLIDATION
30d in phase · OBV NEUTRAL
Current IV 56.8%
IV Percentile 18th %ile
Put/Call OI Skew 1.04x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CDNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NDRA Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $6.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CDNA Moat Profile Scale & Operating Efficiency Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $4.1B market capitalization and 1.6% operating margin.
OpEx & R&D Reinvestment 69.4% of Rev ($345M)
90D Engineering Disclosures 0 Published

Investor FAQ NDRA vs CDNA Key Questions & Quantitative Answers

As of Nov 16, 2026, CareDx, Inc. (CDNA) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NDRA carries a Unified Composite Score of 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin), whereas CDNA carries 24.5/100 (STRONG SELL) at $73.72 (47.1x Forward P/E, 1.6% operating margin). Composite vs. Pillar Nuance: While NDRA currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. CDNA 24.5/100 STRONG SELL), CDNA captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (1.6% vs. 0.0% operating margin) and revenue trajectory (+39.3% vs. +0.0% YoY). Technical & Structure Timing Caution: NDRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7); meanwhile CDNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 49.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CDNA leads the Growth & Scale pillar: NDRA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CDNA at +39.3% YoY revenue growth and N/A YoY earnings growth on $497M TTM revenue (71.0% gross margin, 1.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), NDRA cumulative revenue shifted N/A while CDNA shifted +375.0%. In operating R&D and SG&A reinvestment, NDRA deploys N/A (0 90-day corporate R&D disclosures) versus 69.4% of Rev ($345M) (0 disclosures) for CDNA.

CDNA screens cheaper on headline valuation multiples. NDRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CDNA trades at 47.1x Forward P/E, 32.9x Trailing P/E, N/M PEG, and 7.8x EV/Revenue (12.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NDRA (-152.0% ROE) versus CDNA (33.0% ROE) capital efficiency.

In options market volatility and institutional positioning, NDRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 48% Vol realized risk). By comparison, CDNA carries 56.8% implied volatility (18th %ile, Compressed (<25th %ile)), a 1.04x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.21β · 98% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.